The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index; 8 of the 109 sources its claims cite were checked for support.
Cytokine Storm
Open accessAbstract
Cardiac disorders CTCAE Term Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Pericarditis Asymptomatic, ECG or physical findings (e.g., rub) consistent with pericarditis Definition: A disorder characterized by flaky and dull skin; the pores are generally fine, the texture is a papery thin texture.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review proposes a unifying definition of cytokine storm as elevated circulating cytokine levels, acute systemic inflammatory symptoms, and secondary organ dysfunction beyond a normal pathogen response (or cytokine-driven organ dysfunction if no pathogen is present). It synthesizes mechanisms, causes, and treatments across iatrogenic, pathogen-induced, neoplastic/autoimmune/monogenic, and Covid-19-associated cytokine storm.
Key findings
- The authors propose three criteria for cytokine storm: elevated circulating cytokine levels, acute systemic inflammatory symptoms, and either secondary organ dysfunction due to inflammation beyond that attributable to a normal pathogen response (if a pathogen is present) or any cytokine-driven organ dysfunction (if no pathogen is present). Improvement with cytokine neutralization or antiinflammatory agents further supports the classification.
- Key cytokines implicated include interferon-γ, interleukin-1, interleukin-6, TNF, and interleukin-18. Interleukin-6 is highly elevated in CAR T-cell therapy–induced cytokine storm and several other cytokine storm disorders; tocilizumab and siltuximab have shown effectiveness in HLH, idiopathic multicentric Castleman’s disease, and CAR T-cell–induced cytokine storm. Emapalumab was recently approved for primary HLH, and anakinra is effective in some forms of cytokine storm.
- Causes span iatrogenic triggers (CAR T cells, blinatumomab, TGN1412, rituximab, gene therapies, immune checkpoint inhibitors, cardiac-bypass surgery, allogeneic stem-cell transplantation), pathogens (sepsis, EBV/CMV-associated HLH, HHV-8–associated multicentric Castleman’s disease, influenza), monogenic/autoimmune disorders (primary HLH mutations in PRF1, UNC13D, STXBP1, RAB27A, STX11, SH2D1A, XIAP, NLRC4; autoinflammatory diseases), and Covid-19.
- In Covid-19, elevated cytokines include interleukin-1β, interleukin-6, IP-10, TNF, interferon-γ, MIP1α and MIP1β, and VEGF; higher interleukin-6 levels are strongly associated with shorter survival. Dexamethasone reduces mortality among the most severe cases with elevated CRP and supplemental oxygen requirements, whereas two large randomized controlled trials of anti–interleukin-6 receptor therapies did not show a survival benefit in hospitalized patients with Covid-19.
Methods
- Narrative review; no primary study design, sample, or statistical analysis is reported. The authors synthesize literature and propose a unifying definition and conceptual framework for staging, assessment, and treatment of cytokine storm.
- The review discusses pathophysiological features, clinical presentation, management, and iatrogenic, pathogen-induced, neoplasia-induced, monogenic, and Covid-19–associated causes. No systematic search strategy or meta-analysis is described.
Limitations
- Stated: no single definition of cytokine storm or cytokine release syndrome is widely accepted, and there is disagreement about how these disorders differ from an appropriate inflammatory response; the National Cancer Institute CTCAE definition is too broad, and the American Society for Transplantation and Cellular Therapy definition focuses too specifically on iatrogenic causes.
- Stated: the authors do not propose a specific threshold for cytokine elevations above normal or recommend specific cytokine panels or particular cytokines that must be elevated, given the lack of available evidence; they call for future systematic assessment by a multidisciplinary consortium.
- Stated and evident: mechanisms of Covid-19–associated cytokine storm remain unclear, including whether immune hyperactivity or failure to resolve inflammation underlies severe cases; as a narrative review, it provides no primary data, systematic search, or formal risk-of-bias assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
83 Not checked yet · 51 Own interpretation · 40 No basis given · 3 Partly supported · 1 Supported · 1 Not supported · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Likewise, biomarkers were recently shown to effectively predict which patients with adult-onset Still’s disease would have a response to anakinra or tocilizumab.111”
§ Cytokine Storm > Therapeutics
What the sources say
- Disputedcites [111] Vercruysse F, Barnetche T, Lazaro E, et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 2019; 21: 53- 53. 30755262 PMC6373016 sourceExperimental — accuracy not yet measured
The Results section on predictive factors (page not available) says that no biological variable was statistically predictive of treatment response. It instead associates clinical phenotype and arthritis status with preferential responses to anakinra or tocilizumab; the suggested association with thrombocytosis was not statistically significant. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“The relative frequencies of circulating activated CD4+ and CD8+ T cells and plasmablasts are increased in Covid-19.92”
§ Cytokine Storm > Covid-19–Associated Cytokine Storm
What the sources say
- Supportedcites [92] Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 2020; 369(6508): eabc8511- eabc8511. 32669297 PMC7402624 source
The CD8 and CD4 T-cell activation sections report increased frequencies of activated cells in COVID-19 patients compared with controls (Figs. 2 and 3). The B-cell section reports often markedly increased frequencies of circulating plasmablasts (Fig. 4). The responses were heterogeneous: roughly one-third of patients did not show increased T-cell activation or plasmablast frequencies. (LLM, conf=0.90)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“reports of hemophagocytosis and elevated cytokine levels — as well as beneficial effects of immunosuppressant agents — in affected patients, particularly those who are the most severely ill, suggest that cytokine storm may contribute to the pathogenesis of Covid-19.87,88”
§ Cytokine Storm > Covid-19–Associated Cytokine Storm
What the sources say
- Not checked yetcites [87] Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368: 473- 474. 32303591 source
- Partly supportedcites [88] The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. DOI: 10.1056/NEJMoa2021436. 32678530 PMC7383595 sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) reports elevated inflammatory markers, including interleukin-1 and interleukin-6, in some patients with severe Covid-19. The Discussion (page unavailable) reports a mortality benefit from dexamethasone in patients receiving respiratory support and suggests immunopathological elements may dominate later illness. These passages support the proposed inflammatory contribution, but the paper does not report hemophagocytosis. (LLM, conf=0.86)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Further support comes from positive anecdotal reports of targeted antagonists against interleukin-1, granulocyte–macrophage colony-stimulating factor, and JAK1 and JAK2 in patients with Covid-19.102-105”
§ Cytokine Storm > Covid-19–Associated Cytokine Storm
What the sources say
- Partly supportedcites [102] Fajgenbaum DC, Khor JS, Gorzewski A, et al. Treatments administered to the first 9152 reported cases of COVID-19: a systematic review. Infect Dis Ther 2020; 9: 435- 449. 32462545 PMC7251321 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies IL-1 and JAK/STAT as treatment targets in related cytokine-storm disorders and suggests that anakinra may help control COVID-19 cytokine storms. It does not report positive COVID-19 anecdotes for IL-1, GM-CSF, or JAK1/JAK2 antagonists; its positive anecdotal report concerns tocilizumab, an IL-6 receptor blocker. (LLM, conf=0.83)
- Supportedcites [103] De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol 2020; 2(8): e465- e473. 32835256 PMC7430344 source
The Discussion reports encouraging preliminary results for mavrilimumab, a GM-CSF receptor antagonist, in patients with COVID-19 pneumonia. This supports the GM-CSF portion of the sentence; the other targets are covered by the sentence’s other citations. The paper cautions that controlled trials are needed. (LLM, conf=0.91)
- Supportedcites [104] Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest 2020 November 03 (Epub ahead of print). 32809969 PMC8016181 source
The Introduction identifies baricitinib as a JAK1/JAK2 inhibitor. The section “Baricitinib improves clinical parameters of SARS-CoV-2 infection” reports favorable outcomes in treated COVID-19 patients, including faster reduction in oxygen-flow need, while noting that clinical benefit requires confirmation in randomized trials. This source supports the JAK1/JAK2 part of the multi-citation sentence; the other antagonists are not attributed specifically to it. (LLM, conf=0.91)
- Supportedcites [105] Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuete JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology (Oxford) 2020 October 06 (Epub ahead of print). 33020836 PMC7665718 source
This source supports the JAK1/JAK2 part of the multi-citation sentence, not the interleukin-1 or granulocyte-macrophage colony-stimulating factor parts. Its Discussion reports improved respiratory function with baricitinib plus corticosteroids in patients with moderate to severe SARS-CoV-2 pneumonia; its References identify baricitinib as a JAK1/JAK2 inhibitor. The copy provides section labels but no page numbers for these passages. (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although the initial drivers may differ, late-stage clinical manifestations of cytokine storm converge and often overlap.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The laboratory findings in cytokine storm are variable and influenced by the underlying cause.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the line between a normal and a dysregulated response to a severe infection is blurry”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: unclear — It is unclear whether it could be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: The immune system is expected to recognize foreign invaders, respond proportionally to the pathogen burden, and then return to homeostasis.
In the paper
“Levels of serum cytokines — most prominently, interferon-γ — are often more elevated in patients with cytokine storm due to CAR T-cell therapy than in patients with sepsis-induced cytokine storm”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
What the sources say
- Not checked yetcites [12] Diorio C, Shaw PA, Pequignot E, et al. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Adv 2020; 4: 5174- 5183. 33095872 PMC7594400 source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The neurologic toxic effects are often delayed, developing several days after the onset of the cytokine storm.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
What the sources say
- Not checked yetcites [7] Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625- 638. 30592986 PMC12180426 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Prominent elevations in serum inflammatory cytokine levels, such as interferon-γ (or CXCL9 and CXCL10, chemokines induced by interferon-γ), interleukin-6, interleukin-10, and soluble interleukin-2 receptor alpha, a marker of T-cell activation, are usually present.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 59
- Probably not a substantial claim. 52
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As with EBV-associated HLH,71 rituximab is highly effective in patients with HHV-8–associated multicentric Castleman’s disease, since B-cell depletion removes the primary reservoir for HHV-8.72”
§ Cytokine Storm > Pathogen-Induced Cytokine Storm
What the sources say
- Partly supportedcites [71] Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 2013; 162: 376- 382. 23692048 PMC3776423 sourceExperimental — accuracy not yet measured
This source is citation 71, attached to the comparison with EBV-associated HLH; the HHV-8 claim has a separate citation. The Results report clinical improvement in 43% of patients receiving rituximab-containing regimens, but the Discussion says the retrospective study cannot determine rituximab’s efficacy on its own. It therefore does not support calling rituximab highly effective for EBV-associated HLH. (LLM, conf=0.86)
- Not checked yetcites [72] Dalla Pria A, Pinato D, Roe J, Naresh K, Nelson M, Bower M. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. Blood 2017; 129: 2143- 2147. 28143881 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“certain cytokines may be both helpful in controlling an infection and harmful to the host”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Many patients have hypertriglyceridemia and various blood-count abnormalities, such as leukocytosis, leukopenia, anemia, thrombocytopenia, and elevated ferritin and d-dimer levels.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These symptoms may be due directly to cytokine-induced tissue damage or acute-phase physiological changes or may result from immune-cell–mediated responses.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“No single definition of cytokine storm or the cytokine release syndrome is widely accepted”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In severe cases of cytokine storm, renal failure, acute liver injury or cholestasis, and a stress-related or takotsubo-like cardiomyopathy can also develop.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
What the sources say
- Not checked yetcites [9] Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med 2015; 373: 929- 938. 26332547 source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CAR T-cell therapy and other noninfectious causes can also occur with infections, and infections can develop during the course of therapy, so continued monitoring for infections is warranted.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Cytokine storm is an umbrella term encompassing several disorders of immune dysregulation characterized by constitutional symptoms, systemic inflammation, and multiorgan dysfunction that can lead to multiorgan failure if inadequately treated”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“The National Cancer Institute’s definition, based on the Common Terminology Criteria for Adverse Events (CTCAE), is too broad, since the criteria for an inflammatory syndrome can also apply to other physiological states”
What the sources say
- Not checked yetcites [7] Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625- 638. 30592986 PMC12180426 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Changes in circulating cell counts are most likely due to a complex interplay among cytokine-induced changes in production and mobilization of cells from the bone marrow, immune-mediated destruction, and chemokine-induced migration.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The combination of hyperinflammation, coagulopathy, and low platelet counts places patients with cytokine storm at high risk for spontaneous hemorrhage.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“the definition of the American Society for Transplantation and Cellular Therapy is based on criteria that focus too specifically on iatrogenic causes of cytokine storm alone”
What the sources say
- Not checked yetcites [7] Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625- 638. 30592986 PMC12180426 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“there is disagreement about how these disorders differ from an appropriate inflammatory response”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Nonspecific markers of inflammation such as C-reactive protein (CRP) are universally elevated and correlate with severity.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
What the sources say
- Not checked yetcites [11] Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188- 195. 24876563 PMC4093680 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“patients may have fatigue, anorexia, headache, rash, diarrhea, arthralgia, myalgia, and neuropsychiatric findings”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Disorders that should be ruled out in considering cytokine storm include anaphylaxis and physiological responses to microbial infections.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Cases can progress rapidly to disseminated intravascular coagulation with either vascular occlusion or catastrophic hemorrhages, dyspnea, hypoxemia, hypotension, hemostatic imbalance, vasodilatory shock, and death.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“the fever may be high grade in severe cases”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
What the sources say
- Not checked yetcites [8] Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509- 1518. 23527958 PMC4058440 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Cytokine storm and cytokine release syndrome are life-threatening systemic inflammatory syndromes involving elevated levels of circulating cytokines and immune-cell hyperactivation that can be triggered by various therapies, pathogens, cancers, autoimmune conditions, and monogenic disorders.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Many patients have respiratory symptoms, including cough and tachypnea, that can progress to acute respiratory distress syndrome (ARDS), with hypoxemia that may require mechanical ventilation.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Interferon-γ can induce hemophagocytosis by macrophages, and this may contribute to the cytopenias commonly observed in patients with cytokine storm.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cell Types Involved in Cytokine Storm
What the sources say
- Not checked yetcites [16] Zoller EE, Lykens JE, Terrell CE, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 2011; 208: 1203- 1214. 21624938 PMC3173248 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas similarly high levels of cytokines in cancer-associated HLH or idiopathic multicentric Castleman’s disease would be considered a pathologic state of cytokine storm because no pathogen requiring an immune response is involved and patients benefit from treatment with cytokine neutralization and other antiinflammatory agents.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“At increased levels, cytokines can have systemic effects and cause collateral damage to vital organ systems.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“Th17 cells have a major role in host defense, particularly antifungal protection, and abnormal Th17-cell function can lead to autoimmunity.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cell Types Involved in Cytokine Storm
What the sources say
- Not checked yetcites [24] Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485- 517. 19132915 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, lack of a treatment response does not necessarily rule out cytokine storm, because underlying conditions are likely to play a part, a different cytokine may be the disease driver, or the timing of treatment may have been poor.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Excess interleukin-6 may mediate the impairment in NK-cell function by lowering perforin and granzyme production.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cell Types Involved in Cytokine Storm
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Regulatory cell types, decoy receptors for proinflammatory cytokines such as IL1RA, and antiinflammatory cytokines such as interleukin-10 are important for antagonizing inflammatory-cell populations and preventing immune hyperactivity.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Neutrophils can produce neutrophil extracellular traps, a network of fibers that contribute to thrombi formation and amplify cytokine production during cytokine storm.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cell Types Involved in Cytokine Storm
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Cytokines play a key role in coordinating antimicrobial effector cells and providing regulatory signals that direct, amplify, and resolve the immune response.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“an inappropriate or ineffective amplitude of response, involving excessive effector immune-cell activation (e.g., in cytokine storm due to CAR T-cell therapy), an overwhelming pathogen burden (e.g., in sepsis), or uncontrolled infections and prolonged immune activation”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For the grading of cytokine storm due to other causes, the immune systems disorders section of CTCAE is used”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“HScore and MS score are used for classifying HLH-associated cytokine storm, and HLH-2004 guides treatment.”
§ Cytokine Storm > Clinical Features and Laboratory Abnormalities
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Circulating cytokine levels can be difficult to measure because cytokines have short half-lives, circulating levels may not accurately reflect local tissue levels, and measurements may not be easily obtained worldwide.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
- Rests on an assumption: Cytokines have short half-lives, which normally prevents them from having effects outside lymphoid tissue and sites of inflammation.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Inflammation involves a set of biologic mechanisms that evolved in multicellular organisms to contain invasive pathogens and resolve injuries by activating innate and adaptive immune responses.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In short, cytokine storm involves an immune response that causes collateral damage, which may be greater than the immediate benefit of the immune response.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Rests on an assumption: The immune system is expected to recognize foreign invaders, respond proportionally to the pathogen burden, and then return to homeostasis.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Improvement in outcomes with cytokine neutralization or antiinflammatory agents further supports the pathologic role of excessive cytokines and the classification of a condition as a cytokine storm.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Th1 cells produce large quantities of interferon-γ, induce delayed hypersensitivity reactions, activate macrophages, and are essential for defense against intracellular pathogens.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cell Types Involved in Cytokine Storm
What the sources say
- Not checked yetcites [19] Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145- 173. 2523712 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This response requires a balance between sufficient cytokine production to eliminate the pathogen and avoidance of a hyperinflammatory response in which an overabundance of cytokines causes clinically significant collateral damage.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Rests on an assumption: The immune system is expected to recognize foreign invaders, respond proportionally to the pathogen burden, and then return to homeostasis.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although typically considered to be pathologic, sustained production of cytokines that leads to elevated circulating levels may be necessary to appropriately control some disseminated infections.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In many forms of cytokine storm, macrophages become activated and secrete excessive amounts of cytokines, ultimately causing severe tissue damage that can lead to organ failure.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cell Types Involved in Cytokine Storm
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The cytolytic function of NK cells is diminished in some forms of cytokine storm, which can lead to prolonged antigenic stimulation and difficulty resolving inflammation.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cell Types Involved in Cytokine Storm
What the sources say
- Not checked yetcites [17] Perez N, Virelizier J-L, Arenzana-Seisdedos F, Fischer A, Griscelli C. Impaired natural killer activity in lymphohistiocytosis syndrome. J Pediatr 1984; 104: 569- 573. 6368780 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Interleukin-1 is encoded by two genes (IL1A and IL1B), both of which bind to the same interleukin-1 receptor, activating a cascade of intracellular signaling pathways, including nuclear factor κB (NF-κB).”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The interleukin-1–receptor antagonist anakinra is effective as a single agent and in combination with other agents for the treatment of some forms of cytokine storm.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
What the sources say
- Not checked yetcites [33] Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2020; 72: 326- 334. 31513353 source
- Not checked yetcites [34] Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. J Rheumatol 2010; 37: 879- 880. 20360206 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Interleukin-6 is one of the more complex cytokines, since it is produced by and acts on immune and nonimmune cells across multiple organ systems.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Interferon-γ, interleukin-1, interleukin-6, TNF, and interleukin-18 are key cytokines that often have elevated levels in cytokine storm and are thought to have central immunopathologic roles.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Interferon-γ is primarily secreted by activated T cells and NK cells and is a potent activator of macrophages.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Membrane-bound gp130 is ubiquitously expressed, whereas expression of membrane-bound interleukin-6R is restricted largely to immune cells.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“B cells are not often associated with the pathogenesis of cytokine storm.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cell Types Involved in Cytokine Storm
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Emapalumab, a monoclonal antibody that binds interferon-γ, was recently approved for the treatment of cytokine storm in patients with primary HLH.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
What the sources say
- Not checked yetcites [32] Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med 2020; 382: 1811- 1822. 32374962 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Fever, a clinical hallmark of cytokine storm, can be elicited by interleukin-1, interleukin-6, or TNF through distinct mechanisms.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The specific immune cells that secrete the various cytokines are not fully understood and most likely vary among cytokine storm disorders.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Clinically, interferon-γ causes fever, chills, headache, dizziness, and fatigue.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
What the sources say
- Not checked yetcites [31] Vadhan-Raj S, Nathan CF, Sherwin SA, Oettgen HF, Krown SE. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion. Cancer Treat Rep 1986; 70: 609- 614. 3085930
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In cis signaling, soluble interleukin-6 binds to membrane-bound interleukin-6R, forming an interleukin-6–interleukin-6R complex that binds to gp130, which then initiates signaling through its intracellular domain.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“It can signal through two main pathways, referred to as classic cis signaling and trans signaling.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
What the sources say
- Not checked yetcites [38] Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity 2019; 50: 1007- 1023. 30995492 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The membrane-bound interleukin-6R does not possess intracellular signaling domains but signals instead through interaction with membrane-bound gp130.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This agent may also be useful in other cytokine storm disorders, such as macrophage activation syndrome or CAR T-cell–associated cytokine storm, although in the latter case, it may diminish antitumor effects.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In addition to inducing fever, augmenting systemic inflammation, and activating antimicrobial responses such as interleukin-6, TNF can induce cellular apoptosis and regulate immunity.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The interleukin-18 receptor is constitutively expressed on NK cells and induced on activation in most T cells.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“TNF and other cytokines in the TNF–TNF receptor superfamily are potent inducers of NF-κB, leading to the expression of multiple proinflammatory genes.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This results in systemic hyperinflammation involving secretion of monocyte chemoattractant protein 1 (MCP-1), interleukin-8, and additional interleukin-6, as well as increased vascular endothelial growth factor (VEGF) and reduced E-cadherin expression on endothelial cells, which contribute to vascular hyperpermeability, leakiness, hypotension, and pulmonary dysfunction.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
What the sources say
- Not checked yetcites [38] Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity 2019; 50: 1007- 1023. 30995492 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The effectiveness of anti-TNF therapies in certain autoinflammatory-driven cytokine storm conditions points to their potential role in the treatment of cytokine storm, but the limitations and dangers of anti-TNF therapies in patients with sepsis indicate that more work is needed.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The inflammasome is a multimolecular cytosolic sensor that detects pathogenic microorganisms and sterile stressors and activates caspase-1 during the process of pyroptosis, which, in turn, causes the inactive precursor forms of interleukin-1β and interleukin-18 to become the active forms.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
What the sources say
- Not checked yetcites [41] Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237- 241. 16407889 source
- Not checked yetcites [42] Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ 2019; 26: 99- 114. 30341423 PMC6294779 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“interleukin-18 is a biomarker of severity that correlates with hyperferritinemia, elevated aminotransferase levels, and disease flare.45”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
What the sources say
- Not checked yetcites [45] Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010; 49: 1645- 1653. 20472718 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Most important, it synergizes with interleukin-12 or interleukin-15 to stimulate secretion of interferon-γ from T cells and NK cells, and thus promotes Th1-type inflammatory responses.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“TNF is a potent, multifunctional, proinflammatory cytokine that belongs to the TNF–TNF receptor superfamily.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Interleukin-18 is a member of the large interleukin-1 family40 that has recently been associated with cytokine storm disorders.”
§ Cytokine Storm > Pathophysiological Features of Cytokine Storm > Cytokines
What the sources say
- Not checked yetcites [40] Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013; 39: 1003- 1018. 24332029 PMC3933951 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“possibly because of lower interleukin-6 production by NK cells than by T cells and different cross-talk with myeloid cells.”
§ Cytokine Storm > Iatrogenic Cytokine Storm
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“In a recent study of NK-cell CAR therapy, there were no reported cases of cytokine storm or even elevated interleukin-6 levels,60”
§ Cytokine Storm > Iatrogenic Cytokine Storm
What the sources say
- Not checked yetcites [60] Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 2020; 382: 545- 553. 32023374 PMC7101242 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Like CAR T cells, activated T cells initiate the cytokine storm, and macrophage activation propagates blinatumomab-induced cytokine storm, which also responds to anti–interleukin-6 antibody therapy.36”
§ Cytokine Storm > Iatrogenic Cytokine Storm
What the sources say
- Not checked yetcites [36] Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121: 5154- 5157. 23678006 PMC4123427 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“For example, patients lacking functional perforin, which is critical for resolving infections and inflammation, have prolonged CD8+ T-cell production of interferon-γ and TNF, and HLH-associated cytokine storm develops in such patients when they are infected with EBV or cytomegalovirus.64”
§ Cytokine Storm > Pathogen-Induced Cytokine Storm
What the sources say
- Not checked yetcites [64] Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. Blood 2011; 118: 618- 626. 21606480 PMC3142903 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“recent studies in mice suggest that the cytokines and factors mediating the severity of cytokine storm are produced not by the CAR T cells but by macrophages and can be reversed by interleukin-6 and interleukin-1 blockade.52-54”
§ Cytokine Storm > Iatrogenic Cytokine Storm
What the sources say
- Not checked yetcites [52] Singh N, Hofmann TJ, Gershenson Z, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 2017; 19: 867- 880. 28506444 PMC6676485 source
- Not checked yetcites [53] Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 2018; 24: 731- 738. 29808005 PMC6410714 source
- Not checked yetcites [54] Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 2018; 24: 739- 748. 29808007 source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Since interleukin-6 blockade is highly effective at reversing symptoms and organ dysfunction in most patients, it is the likely cytokine driver of cytokine storm induced by CAR T-cell therapy.”
§ Cytokine Storm > Iatrogenic Cytokine Storm
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Patients with HHV-8–associated multicentric Castleman’s disease are immunocompromised as a result of human immunodeficiency virus infection or a genetic susceptibility, making it difficult to control the HHV-8 infection, which is a common, typically asymptomatic infection in the general population.69”
§ Cytokine Storm > Pathogen-Induced Cytokine Storm
What the sources say
- Not checked yetcites [69] Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood 2020; 135: 1353- 1364. 32106302 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Though data on relative frequencies are limited, infections are most likely the most common trigger of cytokine storm.”
§ Cytokine Storm > Pathogen-Induced Cytokine Storm
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the pathogen initiates and T-cell activation propagates cytokine storm in patients with a genetic susceptibility.”
§ Cytokine Storm > Pathogen-Induced Cytokine Storm
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A recent study showed that the effect of tocilizumab in patients with HHV-8–associated multicentric Castleman’s disease was minimal and short-lived, most likely because of viral interleukin-6 signaling that was independent of the neutralized interleukin-6 receptor.70”
§ Cytokine Storm > Pathogen-Induced Cytokine Storm
What the sources say
- Not checked yetcites [70] Ramaswami R, Lurain K, Peer CJ, et al. Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 2020; 135: 2316- 2319. 32276276 PMC7316216 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Generalized T-cell and B-cell ablation with alemtuzumab and T-cell ablation with antithymocyte globulin have been reported; ablation most likely works by depleting the pathogenic CD8+ T cells, among other cell types.76”
§ Cytokine Storm > Monogenic or Autoimmune Cytokine Storm
What the sources say
- Not checked yetcites [76] Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2013; 60: 101- 109. 22522603 PMC3410971 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In patients with secondary HLH, viral, autoimmune, or neoplastic disorders trigger cytokine storm, and such patients often have heterozygous polymorphisms in the same genes that are altered in primary HLH.65,74”
§ Cytokine Storm > Monogenic or Autoimmune Cytokine Storm
What the sources say
- Not checked yetcites [65] Zhang M, Bracaglia C, Prencipe G, et al. A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis. J Immunol 2016; 196: 2492- 2503. 26880764 PMC4779709 source
- Not checked yetcites [74] Kaufman KM, Linghu B, Szustakowski JD, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2014; 66: 3486- 3495. 25047945 PMC4321811 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Cytokine storm was also reported in patients with SARS and was associated with poor outcomes.86”
§ Cytokine Storm > Covid-19–Associated Cytokine Storm
What the sources say
- Not checked yetcites [86] Huang K-J, Su I-J, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol 2005; 75: 185- 194. 15602737 PMC7166886 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Given the primary genetic defects and the effective treatments that are available, innate cells are most likely the primary cell drivers involved, and TNF, interleukin-1, interleukin-18, or a combination of these cytokines probably drives pathogenesis.”
§ Cytokine Storm > Monogenic or Autoimmune Cytokine Storm
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“a recent randomized, controlled trial showing that dexamethasone reduces mortality among the most severe cases of Covid-19, characterized by elevated CRP levels and supplemental oxygen requirements, and potentially worsens outcomes in milder cases suggests that excessive, late-stage inflammation contributes to mortality.88”
§ Cytokine Storm > Covid-19–Associated Cytokine Storm
What the sources say
- Not checked yetcites [88] The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. DOI: 10.1056/NEJMoa2021436. 32678530 PMC7383595 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Host immune responses and immune-related symptoms are extremely variable between asymptomatic patients (who have effective control of SARS-CoV-2) and patients with severe Covid-19 (who are unable to control the virus), which suggests that host immune dysregulation contributes to pathogenesis in some cases.”
§ Cytokine Storm > Covid-19–Associated Cytokine Storm
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“blocking a cytokine with a low or normal circulating level can be effective if it is a key component of the hyperinflammatory circuit or if its level is potentially elevated in tissue.”
§ Cytokine Storm > Therapeutics
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“combination therapy has more potential risks than single-agent therapy.”
§ Cytokine Storm > Therapeutics
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“An observational study suggesting that patients with Covid-19 have a good response to glucocorticoids when the CRP level is high but a poor response when the level is low is consistent with these findings.101”
§ Cytokine Storm > Covid-19–Associated Cytokine Storm
What the sources say
- Not checked yetcites [101] Keller MJ, Kitsis EA, Arora S, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J Hosp Med 2020; 15: 489- 493. 32804611 PMC7518134 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All targeted agents have target-specific risks”
§ Cytokine Storm > Therapeutics
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Likewise, the observation that proinflammatory agents such as inhaled interferon-β have a positive effect if given early in the disease course is consistent with a model in which immunostimulation that enhances antiviral activity is helpful early (and probably harmful late), whereas immunosuppression is helpful late and harmful early.”
§ Cytokine Storm > Covid-19–Associated Cytokine Storm
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The immune response to SARS-CoV-2 is critical for controlling viral replication and clearance.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“pathologic hyperinflammation itself is an immunodeficiency that can put patients at risk for infections”
§ Cytokine Storm > Therapeutics
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Targeted therapeutic approaches to cytokine storm associated with idiopathic multicentric Castleman’s disease, HLH, or CAR T-cell therapy have turned deadly conditions into often reversible states.”
§ Cytokine Storm > Summary
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper relies on this without support.
The immune system is expected to recognize foreign invaders, respond proportionally to the pathogen burden, and then return to homeostasis.
“The immune system is expected to recognize foreign invaders, respond proportionally to the pathogen burden, and then return to homeostasis.”
The paper relies on this without support.
Cytokines have short half-lives, which normally prevents them from having effects outside lymphoid tissue and sites of inflammation.
“Cytokines have short half-lives, which normally prevents them from having effects outside lymphoid tissue and sites of inflammation.”
The paper relies on this without support.
The immune response to SARS-CoV-2 is critical for controlling viral replication and clearance.
“when the immune response to SARS-CoV-2 is critical in controlling viral replication and clearance.”
The paper relies on this without support.
No unifying definition of cytokine storm exists.
“No unifying definition of cytokine storm exists”
The paper relies on this without support.
There is much disagreement about what the definition of cytokine storm should be and whether specific conditions such as Covid-19 should be included in the spectrum of cytokine storm disorders.
“there is much disagreement about what the definition should be and whether specific conditions such as Covid-19 should be included in the spectrum of cytokine storm disorders.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This specific activity protects severely infected COVID-19 patients from the cytokine storm (55).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [55]
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
Mosmann, T. R., & Coffman, R. L. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.001045 · Cited by 7,692
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662
Cited by
Sorted by citations
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,153
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Tassell, B. W. V., Dentali, F., Montecucco, F., Maßberg, S., Levi, M. M., et al. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00536-9 · Cited by 1,039
COVID-19 and the human innate immune system
Schultze, J. L., & Aschenbrenner, A. C. (2021) · Cell · doi:10.1016/j.cell.2021.02.029 · Cited by 714
“immune hyperactivation in cytokine storm is the failure of resolution of the inflammation (Fajgenbaum and June, 2020).”
BackgroundTherapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R. J., & Clercq, E. D. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 714
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 618
Bhol, N. K., Bhanjadeo, M. M., Singh, A. K., Dash, U. C., Ojha, R. R., Majhi, S., Duttaroy, A. K., & Jena, A. B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117177 · Cited by 570
CAR T therapy beyond cancer: the evolution of a living drug
Baker, D. J., Arany, Z. P., Baur, J. A., Epstein, J. A., & June, C. H. (2023) · Nature · doi:10.1038/s41586-023-06243-w · Cited by 546
Self-citationPathophysiology of COVID-19-associated acute kidney injury
Legrand, M. M., Bell, S., Forni, L. G., Joannidis, M., Koyner, J. L., Liu, K. D., & Cantaluppi, V. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00452-0 · Cited by 527
Xu, S., Ilyas, I., & Weng, J. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00998-0 · Cited by 483
The ‘cytokine storm’: molecular mechanisms and therapeutic prospects
Karki, R., & Kanneganti, T. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.06.001 · Cited by 464
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Guimarães, P. O., Quirk, D. M., Furtado, R. H. D. M., Maia, L. N., Saraiva, J. F. K., Antunes, M. D. O., Filho, R. K., Junior, V. M., Soeiro, A. M., Tognon, A. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101643 · Cited by 436
Pyroptosis-Induced Inflammation and Tissue Damage
Vasudevan, S. O., Behl, B., & Rathinam, V. A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101781 · Cited by 412
Autophagy in tumour immunity and therapy
Xia, H., Green, D. R., & Zou, W. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00344-2 · Cited by 421
Regulated cell death pathways in kidney disease
Sanz, A. B., Sánchez-Niño, M. D., Ramos, A. M., & Ortíz, A. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00694-0 · Cited by 432
Hypoalbuminemia as Surrogate and Culprit of Infections
Wiedermann, C. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094496 · Cited by 422
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 418
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy
Zanza, C., Romenskaya, T., Manetti, A. C., Franceschi, F., Russa, R. L., Bertozzi, G., Maiese, A., Savioli, G., Volonnino, G., & Longhitano, Y. (2022) · Medicina · doi:10.3390/medicina58020144 · Cited by 413
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 399
Onset and frequency of depression in post-COVID-19 syndrome: A systematic review
Renaud‐Charest, O., Lui, L. M. W., Eskander, S., Ceban, F., Ho, R., Vincenzo, J. D. D., Rosenblat, J. D., Lee, Y. L., Subramaniapillai, M., & McIntyre, R. S. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.09.054 · Cited by 393
Tardif, J., Bouabdallaoui, N., L’Allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., López-Sendón, J. L., da Luz, P. L., Verret, L., Audet, S., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00222-8 · Cited by 361
Karki, R., Lee, S., Mall, R., Nagakannan, P., Wang, Y., Sharma, B. R., Malireddi, R. K. S., Yang, D., Trifkovic, S., Steele, J. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo6294 · Cited by 349
Macrophage Polarity and Disease Control
Kadomoto, S., Izumi, K., & Mizokami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010144 · Cited by 331
Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02148-6 · Cited by 347
PANoptosis : Mechanisms, biology, and role in disease
Sun, X., Yang, Y., Meng, X., Li, J., Liu, X., & Liu, H. (2023) · Immunological Reviews · doi:10.1111/imr.13279 · Cited by 333
Cytokine Storm—Definition, Causes, and Implications
Jarczak, D., & Nierhaus, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911740 · Cited by 336
GM-CSF: A Double-Edged Sword in Cancer Immunotherapy
Kumar, A., Khani, A. T., Ortiz, A. S., & Swaminathan, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901277 · Cited by 287
Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals
Sang, D., Lin, K., Yang, Y., Ran, G., Li, B., Chen, C., Li, Q., Ma, Y., Lu, L., Cui, X., et al. (2023) · Cell · doi:10.1016/j.cell.2023.10.025 · Cited by 281
Monocytes and Macrophages in COVID-19
Knoll, R., Schultze, J. L., & Schulte-Schrepping, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720109 · Cited by 279
Immune Cells and Immunotherapy for Cardiac Injury and Repair
Rurik, J. G., Aghajanian, H. K., & Epstein, J. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318005 · Cited by 275
Kundu, M., Butti, R., Panda, V. K., Malhotra, D., Das, S., Mitra, T., Kapse, P., Gosavi, S., & Kundu, G. C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01990-4 · Cited by 284
Rabaan, A. A., Al-Ahmed, S. H., Muhammad, J., Khan, A., Sule, A. A., Tirupathi, R., Mutair, A. S. A., Alhumaid, S., Al‐Omari, A., Dhawan, M. K., et al. (2021) · Vaccines · doi:10.3390/vaccines9050436 · Cited by 262
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Hwang, Y., Lu, R., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 247
Current status of hand-foot-and-mouth disease
Zhu, P., Ji, W., Li, D., Li, Z., Chen, Y., Dai, B., Han, S., Chen, S., Jin, Y., & Duan, G. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00908-4 · Cited by 230
Innate immune sensing of coronavirus and viral evasion strategies
Kasuga, Y., Zhu, B., Jang, K., & Yoo, J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00602-1 · Cited by 236
Bernard, L., Venzon, M., Klein, J., Axelrad, J. E., Zhang, C., Sullivan, A. P., Hussey, G. A., Casanovas‐Massana, A., Noval, M. G., Valero-Jimenez, A. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33395-6 · Cited by 233
Kang, M., Lee, S. H., Kwon, M., Byun, J., Kim, D., Kim, C., Koo, S., Kwon, S. P., Moon, S., Jung, M., et al. (2021) · Advanced Materials · doi:10.1002/adma.202103258 · Cited by 225
Host genetic factors determining COVID-19 susceptibility and severity
Velavan, T. P., Pallerla, S. R., Rüter, J., Augustin, Y. S., Kremsner, P. G., Krishna, S., & Meyer, C. G. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103629 · Cited by 222
The glycosylation in SARS-CoV-2 and its receptor ACE2
Gong, Y., Qin, S., Dai, L., & Tian, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00809-8 · Cited by 226
Carbone, A., Borok, M. Z., Damania, B., Gloghini, A., Polizzotto, M. N., Jayanthan, R., Fajgenbaum, D. C., & Bower, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00317-7 · Cited by 214
Self-citationSupady, A., Weber, E., Rieder, M., Lother, A., Niklaus, T., Zahn, T., Frech, F., Müller, S., Kuhl, M., Benk, C., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00177-6 · Cited by 205
Deep insight into cytokine storm: from pathogenesis to treatment
Nie, J., Zhou, L., Tian, W., Liu, X., Yang, L., Yang, X., Zhang, Y., Wei, S., Wang, D. W., & Wei, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02178-y · Cited by 251
Peripheral Nervous System Manifestations Associated with COVID-19
Andalib, S., Biller, J., Napoli, M. D., Moghimi, N., McCullough, L. D., Rubiños, C., Nobleza, C. O., Azarpazhooh, M. R., Catanese, L., Elicer, I., et al. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01102-5 · Cited by 198
Cerebral dysfunctions caused by sepsis during ageing
Manabe, T., & Heneka, M. T. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00643-7 · Cited by 191
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
Sukhatme, V. P., Reiersen, A. M., Vayttaden, S. J., & Sukhatme, V. V. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.652688 · Cited by 193
Escandón-Vargas, K., Rasmussen, A. L., Bogoch, I. I., Murray, E. J., Escandón, K., Popescu, S. V., & Kindrachuk, J. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06357-4 · Cited by 206
Drug combination therapy for emerging viral diseases
Shyr, Z. A., Cheng, Y., Lo, D. C., & Zheng, W. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.008 · Cited by 191
SARS-CoV-2 Initiates Programmed Cell Death in Platelets
Koupenova, M., Corkrey, H. A., Vitseva, O. I., Tanrıverdi, K., Somasundaran, M., Liu, P., Soofi, S., Bhandari, R., Godwin, M., Parsi, K. M., et al. (2021) · Circulation Research · doi:10.1161/circresaha.121.319117 · Cited by 186
Macrophages: shapes and functions
Lendeckel, U., Venz, S., & Wolke, C. (2022) · ChemTexts · doi:10.1007/s40828-022-00163-4 · Cited by 215
Secretory autophagy maintains proteostasis upon lysosome inhibition
Solvik, T. A., Nguyen, T. A., Lin, Y.-H. T., Marsh, T., Huang, E. J., Wiita, A. P., Debnath, J., & Leidal, A. M. (2022) · The Journal of Cell Biology · doi:10.1083/jcb.202110151 · Cited by 195
Next-Generation CAR T-cell Therapies
Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N., & June, C. H. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1683 · Cited by 191
Self-citationPro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans: A Mini Review
Wautier, J., & Wautier, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119647 · Cited by 209
Metformin attenuated sepsis-related liver injury by modulating gut microbiota
Liang, H., Song, H., Zhang, X., Song, G., Wang, Y., Ding, X., Duan, X., Li, L., Sun, T., & Kan, Q. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2045876 · Cited by 177
Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword
Tan, L. Y., Komarasamy, T. V., & Balasubramaniam, V. R. M. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742941 · Cited by 184
Efficacy of CytoSorb®: a systematic review and meta-analysis
Becker, S., Lang, H., Barbosa, C. V., Tian, Z., Melk, A., & Schmidt, B. M. W. (2023) · Critical Care · doi:10.1186/s13054-023-04492-9 · Cited by 179
Immunosenescence, Inflammaging, and Frailty: Role of Myeloid Cells in Age-Related Diseases
Bleve, A., Motta, F., Durante, B., Pandolfo, C., Selmi, C., & Sica, A. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08909-7 · Cited by 185
Pathogenicity and virulence of influenza
Liang, Y. (2023) · Virulence · doi:10.1080/21505594.2023.2223057 · Cited by 198
Cesta, M. C., Zippoli, M., Marsiglia, C., Gavioli, E. M., Mantelli, F., Allegretti, M., & BALK, R. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.808797 · Cited by 173
Caricchio, R., Abbate, A., Гордеев, И. Г., Meng, J., Hsue, P. Y., Neogi, T., Arduino, R. C., Fomina, D. S., Bogdanov, R., Stepanenko, T., et al. (2021) · JAMA · doi:10.1001/jama.2021.9508 · Cited by 169
Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection
Smith, N., Gonçalves, P., Charbit, B., Grzelak, L., Beretta, M., Planchais, C., Bruel, T., Rouilly, V., Bondet, V., Hadjadj, J., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01028-7 · Cited by 161
Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G., & Lee, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.704205 · Cited by 166
Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy
Goldman, A., Maor, E., Bomze, D., Liu, J. E., Herrmann, J., Fein, J. A., Steingart, R. M., Mahmood, S., Schaffer, W. L., Perales, M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.044 · Cited by 159
Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
Stravalaci, M., Pagani, I., Paraboschi, E. M., Pedotti, M., Doni, A., Scavello, F., Mapelli, S. N., Sironi, M., Perucchini, C., Varani, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01114-w · Cited by 161
Acute respiratory distress syndrome
Wick, K. D., Ware, L. B., & Matthay, M. A. (2024) · BMJ · doi:10.1136/bmj-2023-076612 · Cited by 185
Moriyama, K., & Nishida, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168882 · Cited by 158
Therapeutic Targeting of NF-κB in Acute Lung Injury: A Double-Edged Sword
Millar, M. W., Fazal, F., & Rahman, A. (2022) · Cells · doi:10.3390/cells11203317 · Cited by 159
MXene-based aptasensors: Advances, challenges, and prospects
Zahra, Q. U. A., Ullah, S., Shahzad, F., Qiu, B., Fang, X., Ammar, A., Luo, Z., & Zaidi, S. A. (2022) · Progress in Materials Science · doi:10.1016/j.pmatsci.2022.100967 · Cited by 155
Mechanisms underlying immunosuppression by regulatory cells
Goldmann, O., Nwofor, O. V., Chen, Q., & Medina, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328193 · Cited by 162
Chen, J., Alfajaro, M. M., Chow, R. D.-W., Wei, J., Filler, R. B., Eisenbarth, S. C., & Wilen, C. B. (2021) · Journal of Virology · doi:10.1128/jvi.00014-21 · Cited by 153
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 170
Cron, R. Q., Goyal, G., & Chatham, W. W. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-112837 · Cited by 149
Labarrere, C. A., & Kassab, G. S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1007816 · Cited by 153
The JAK-STAT pathway: from structural biology to cytokine engineering
Lv, Y., Qi, J., Babon, J. J., Cao, L., Fan, G.-H., Lang, J., Zhang, J., Mi, P., Kobe, B., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01934-w · Cited by 157
The land-scape of immune response to monkeypox virus
Li, H., Huang, Q., Zhang, H., Liu, Z., Chen, X.-H., Ye, L.-L., & Luo, Y. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104424 · Cited by 141
Schlechte, J., Zucoloto, A. Z., Yu, I.-L., Doig, C. J., Dunbar, M., McCoy, K. D., & McDonald, B. (2023) · Nature Medicine · doi:10.1038/s41591-023-02243-5 · Cited by 147
Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy
Jiang, Y.-Z., Rubin, L., Peng, T., Liu, L., Xing, X., Lazarovici, P., & Zheng, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59272 · Cited by 144
The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections
Hsu, R., Yu, W.-C., Peng, G.-R., Ye, C.-H., Hu, S., Chong, P. C. T., Yap, K. Y., Lee, J. Y. C., Lin, W., & Yu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832394 · Cited by 148
Nishimura, Y., Fajgenbaum, D. C., Pierson, S. K., Iwaki, N., Nishikori, A., Kawano, M., Nakamura, N., Izutsu, K., Takeuchi, K., Nishimura, M. F., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26292 · Cited by 138
Self-citationCell‐Based Delivery Systems: Emerging Carriers for Immunotherapy
Li, Z., Wang, Y., Ding, Y., Repp, L., Kwon, G. S., & Hu, Q. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100088 · Cited by 138
Calming the cytokine storm in COVID-19
Cron, R. Q., Caricchio, R., & Chatham, W. W. (2021) · Nature Medicine · doi:10.1038/s41591-021-01500-9 · Cited by 136
COVID-19 and the role of cytokines in this disease
Hasanvand, A. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-00992-2 · Cited by 138
Two Years into the COVID-19 Pandemic: Lessons Learned
da Silva, S. J. R., do Nascimento, J. C. F., Mendes, R. P. G., Guarines, K. M., da Silva, C. T. A., da Silva, P. G., de Magalhães, J. J. F., Vigar, J. R. J., Silva‐Júnior, A., Kohl, A., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00204 · Cited by 155
Meyer, M., Wiberg, S. C., Grand, J., Meyer, A., Obling, L. E. R., Frydland, M. S., Thomsen, J. H., Josiassen, J., Møller, J. E., Kjærgaard, J., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.053318 · Cited by 140
Italia, L., Tomasoni, D., Bisegna, S., Pancaldi, E., Stretti, L., Adamo, M., & Metra, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.713560 · Cited by 140
Disseminated intravascular coagulation and its immune mechanisms
Popescu, N. I., Lupu, C., & Lupu, F. (2021) · Blood · doi:10.1182/blood.2020007208 · Cited by 140
Inflammation: A New Look at an Old Problem
Gusev, E., & Zhuravleva, Y. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094596 · Cited by 151
Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment
Lordan, R., Rando, H. M., & Greene, C. S. (2021) · mSystems · doi:10.1128/msystems.00122-21 · Cited by 137
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary reportPreprint
The REMAP-CAP Investigators, Gordon, A. C., Mouncey, P. R., Al-Beidh, F., Rowan, K., Nichol, A., Arabi, Y. M., Annane, D., Beane, A., van Bentum-Puijk, W., et al. (2021) · medRxiv · doi:10.1101/2021.01.07.21249390 · Cited by 130
Malignancy-associated haemophagocytic lymphohistiocytosis
Setiadi, A., Zoref-Lorenz, A., Lee, C. Y., Jordan, M. B., & Chen, L. Y. C. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00366-5 · Cited by 128
Zhu, K., Qian, S., Guo, H., Wang, Q., Chu, X., Wang, X., Lu, S. T., Peng, Y., Guo, Y., Zhu, Z., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c03971 · Cited by 129
SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels
Eberhardt, N., Noval, M. G., Kaur, R., Amadori, L., Gildea, M. A., Sajja, S., Das, D., Cılhoroz, B., Stewart, O., Fernandez, D. M., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00336-5 · Cited by 132
Role of IL-6 in the commitment of T cell subsets
Korn, T., & Hiltensperger, M. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155654 · Cited by 128
The role of IL-6 and IL-6 blockade in COVID-19
Potere, N., Batticciotto, A., Vecchié, A., Porreca, E., Cappelli, A., Abbate, A., Dentali, F., & Bonaventura, A. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1919086 · Cited by 127
The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients
Perreau, M., Suffiotti, M., Marques-Vidal, P. M., Wiedemann, A., Lévy, Y., Laouenan, C., Ghosn, J., Fenwick, C. W., Comte, D., Roger, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25191-5 · Cited by 123
Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19
Kaiser, R. W. J., Leunig, A., Pekayvaz, K., Popp, O., Joppich, M., Polewka, V., Escaig, R., Anjum, A., Hoffknecht, M., Gold, C., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150862 · Cited by 125
Platelets in the NETworks interweaving inflammation and thrombosis
Wienkamp, A.-K., Erpenbeck, L., & Rossaint, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953129 · Cited by 125
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap
Walker, K. A., Page, L. M. L., Terrando, N., Duggan, M. R., Heneka, M. T., & Bettcher, B. M. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00627-2 · Cited by 121
Saper, V. E., Ombrello, M. J., Tremoulet, A. H., Montero-Martín, G., Prahalad, S., Canna, S., Shimizu, C., Deutsch, G. H., Tan, S. Y., Remmers, E. F., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220578 · Cited by 115
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Mengist, H. M., Kombe, A. J. K., Mekonnen, D. S., Abebaw, A., Getachew, M., & Jin, T. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101533 · Cited by 115
Single-cell immunology of SARS-CoV-2 infection
Tian, Y., Carpp, L. N., Miller, H. E. R., Zager, M. A., Newell, E. W., & Gottardo, R. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01131-y · Cited by 114
Metadata
- Authors
- Fajgenbaum, D. C., & June, C. H.
- Affiliations
- University of Pennsylvania (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- June, Carl H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-03
- Volume
- 383
- Issue
- 23
- Pages
- 2255-2273
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7727315
- OpenAlex
- W3112902030
- Cited by
- 3,196
- References
- 113
- Citations by year
- 2026: 304 · 2025: 438 · 2024: 534 · 2023: 592 · 2022: 711 · 2021: 601 · 2020: 10
- FWCI
- 22.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (2r01hl141408-06)
- National Heart, Lung, and Blood Institute (R01-HL141408)
- National Cancer Institute (P01CA214278)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- cytokine storm, pericarditis, heart disease, CTCAE grading, adverse event definitions
- MeSH terms
- Cytokine Release Syndrome, COVID-19, Autoimmune Diseases, Bacterial Infections, Blood Proteins, Humans, Interleukins, Virus Diseases, Cytokines, Chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review